ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ACHV vs MYGN // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

Achieve Life Sciences Inc. (NASDAQ) VS. Myriad Genetics Inc. (NASDAQ) • 15-METRIC TALLY: ACHV 1 — MYGN 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACHV VS. MYGN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ACHV MYGN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 69.90% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -6.69% 0.28% -6.97 MYGN /fcf-yield <GO>
Operating Margin — -47.00% — TIE /operating-margins <GO>
Net Profit Margin — -44.40% — TIE /net-margins <GO>
Revenue Growth (YoY) — -1.60% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 6/9 -4.00 MYGN /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 46.4 72.7 -26.24 MYGN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $739.9M $638.0M $101.9M ACHV /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ACHV REV MYGN REV ACHV GROSS % MYGN GROSS % ACHV FCF MYGN FCF
FY 2025 $0 $824.5M — 69.9% -$49.5M $1.8M
FY 2024 $0 $837.6M — 69.9% -$29.8M -$8.7M
FY 2023 $0 $753.2M — — -$24.5M -$110.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACHV // BETA —
MYGN // BETA —